UNITAID's 2013 annual report: "Transforming markets, saving lives"

UNITAID
May 24, 2014, 9 p.m.

Report shows UNITAID’s approach vital to remove market barriers so millions can have equitable access to new treatments for infectious diseases

Geneva 20 May 2014 – Highly-effective treatments and diagnostics for HIV, malaria, tuberculosis (TB) are emerging, some for the first time in decades, but UNITAID’s 2013 Annual Report [PDF, 4 MB] shows that considerable ‘market barriers’ need to be removed so these products can reach millions of people in low- and middle-income countries.

Entitled “Transforming Markets, Saving Lives,” this report highlights barriers - including high prices, patents, and the lack of adapted formulations – but also demonstrates how UNITAID is addressing these challenges through investments to shape markets. From accelerating market entry of new and affordable diagnostic tools to stimulating the development of paediatric formulations, the report shows that UNITAID is playing a key – and essential – role.

“This report is especially timely as it follows almost $160 million in new UNITAID market interventions announced on 6 May 2014, including investments to ensure low- and middle-income populations have access to new high performing treatments for hepatitis C and drug-resistant tuberculosis,” said Dr Philippe Douste Blazy, Chairman of the UNITAID Executive Board. “These are the first major global investments in these game-changing medicines from any large funder. “

UNITAID’s Annual Report brings together market intelligence collected by the organization over the year to inform its investments. Among the topics covered in this report:

Download Report 2013 [PDF, 4 MB]


Source: UNITAID